FDA Approves Axicabtagene Ciloleucel for Non-Hodgkin Lymphoma – OncLive
|
FDA Approves Axicabtagene Ciloleucel for Non-Hodgkin Lymphoma
OncLive The FDA has approved the CD19-directed CAR T-cell therapy axicabtagene ciloleucel as a treatment for adults with relapsed or refractory non-Hodgkin … |
